71 results about "Sedative" patented technology

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

The present invention provides accelerated detoxification methods for the treatment of a substance abuse-related condition in a subject. A method of the present invention may comprise administering to the subject an effective amount of at least one sedative (e.g, clonidine, diazepam, or olanzapine) and a micro-dose of an opioid antagonist (e.g., naltrexone or naloxone) for at least one day; optionally administering a small dose of an opiate, and administering to the subject a detoxifying amount of a second opioid antagonist (e.g., naloxone); and may further comprise administering to the subject a third opioid antagonist (such as, naltrexone) for an extended period of time (e.g., 12 months).

A system and method provides closed-loop sedation, anesthesia, or analgesia by monitoring EEG and automatically adjusting the delivery of sedative, anesthetic, and/or analgesic drugs to maintain that desired or predetermined level of cortical at all echelons of care. The system and method further monitor the subject's cortical activity to detect occurrence of burst suppression which can be indicative of unsafe depth of anesthesia or sedation. Further, the system and methods provide for alteration or cessation of the administration of anesthesia or sedation based on the occurrence of burst suppression to mitigate harm to the subject.

The invention discloses an oral sedative for children. The oral sedative comprises the following components: simple syrup, a chloral hydrate solution with the mass concentration of 10%-20%, and a glucose solution, containing sodium citrate, with the mass concentration of 5%-10% according to the volume proportion of the (1-2):2:1, wherein the mass concentration of the glucose solution dissolving sodium citrate is 5%-10%; the main simple syrup component is the simple syrup of cane sugar, and the mixed oral sedative is a weak alkaline solution with the pH value of 7-8. According to the sedative formula of the application, (1) the taste of the conventional chloral hydrate is improved, and the conflict reaction when the sedative is taken by an infant patient is reduced; (2) the effect-taking time of the oral chloral hydrate sedative is shortened, so that the sedative can be absorbed by small intestines relatively easily, the bioavailability is improved, the stimulation on gastrointestinal tracts is reduced, and nausea and vomiting are reduced.

Capsule preparations are produced by using solutions for capsule-filling which contain ibuprofen, polyethylene glycol, water and terpenes (menthol, limonene, borneol, dl-camphor, mentha oil, etc.) optionally together with one or more drugs selected from among antipyretic analgesics, antihistamines, antitussives, expectorants, sympathetic stimulant, analeptics, hypnotic sedatives and anti-inflammatory agents, solubilizers, thickeners, pH controlling agents, colorants, etc. Thus, it is attempted to relieve the bitterness of ibuprofen and establish an immediate action at the same time.

A mandibular and neck support and positioning device intended to keep the airways unobstructed, facilitating breathing in patients with trauma or under anesthesia, on sedatives or in deep relaxation, where the device has a base support for at least the patient's neck, the base support has at least two pusher parts located on the sides to lift the mandible and, once fixed, said side pieces remain in place whenever a new position needs to be adopted.

The invention discloses an additive increasing a survival rate of live fish transportation, and belongs to the field of aquatic product transportation. The additive is prepared from, by mass, 10-50% of coarse salt, 5-8% of an isatis root extract, 10-30% of pregelatinized starch, 8-12% of vitamin C, 8-12% of vitamin B2, 10-12% of glucose and 20-40% of dried ginger. The additive can significantly increase the survival rate of live fish transportation, does not have drug harm effects of other anaesthetic sedatives, is low in cost, convenient to use, does not need intramuscular injection and othercumbersome operation, and is suitable for economical fish transportation.

The invention provides a pediatric anesthesia induction oral administration formulation and a preparation method thereof. The formulation consists of a solid sedative and a plastic inner core, wherein the solid sedative consists of cane sugar, maltose and raw material medicaments; the plastic inner core consists of a spherical plastic core and a plastic rod; the solid sedative is coated on the surface of the spherical plastic core; and the spherical plastic core consists of a spherical inner core and ridge-shaped convex strips which are symmetrically and longitudinally distributed on the surface of the spherical inner core. The preparation method comprises the following steps of: mixing the cane sugar and the maltose; heating under normal pressure and stirring to obtain syrup; adding the raw material medicaments into the syrup according to the amount of the sedative; stirring until the raw material medicaments are fully dissolved to obtain a liquid sedative; and uniformly coating the liquid sedative onto the surface of the spherical plastic core and naturally cooling for molding to obtain the pediatric anesthesia induction oral administration formulation. The pediatric anesthesia induction oral administration formulation is in the lollipop form, is easily accepted by children, makes induction convenient and practicable and avoids the undesirable psychological effects of intramuscular injection and intravenous injection on the children.

A system comprising means for obtaining a signal representative of the electrocortical activity of the patient, means for analyzing this signal in order to derive from it a signal of depth of anaesthesia, means for monitoring the value and development over time of this signal of depth of anaesthesia, these means being associated with means for calculation of control commands of the injection means, in order to regulate automatically in closed loop the signal of depth of anaesthesia in a predetermined range around a target value, and in that the means for injection of anaesthetics comprise first means for injection of a hypnotic that receive control commands at a first frequency, and second means for injection of a morphinomimetic that receive control commands at a second frequency higher than the first frequency.

The invention discloses a pharmaceutical composition containing propofol and opioid analgesics and a use thereof. The pharmaceutical composition comprises pharmaceutically acceptable carriers, propofol as a first active component and opioid analgesics as second active components selected from fentanyl, remifentanil, sufentanil and alfentanil. The pharmaceutical composition containing propofol and opioid analgesics utilizes the combination of narcotic analgesics and a narcotic sedative, has effects of analgesia and sedation, reduces the frequency of drug administration carried out by an analgesist, makes an anesthesia induction process more convenient, obviously reduces an incidence rate and the severity of the propofol injection pain, and reduces adverse reactions of monotherapy.

The invention discloses L-citrulline succinate and a preparation method and application thereof. The method comprises the steps of firstly preparing an L-citrulline water solution, adding succinic acid powder to the solution, and carrying out stirring reaction to obtain an L-citrulline succinate solution; and separating out the L-citrulline succinate solution in a crystal form. The method is simple, feasible, low in production cost, high in product yield and high in purity; and industrial popularization can be carried out. Through the L-citrulline succinate, blood vessels of a person can be relaxed; and the L-citrulline succinate is used for strengthening the male sexual function, keeping cholesterol at a normal level and synthesizing an antidote and a sedative.

Rapid opioid detoxification procedures are provided which include sedating a patient with an anesthetic agent having a short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification also include administering a diarrhea suppressant, such as octreotide acetate, to limit this unfortunate side effect of the detoxification.

The invention provides a glossy ganoderma-ginseng sedative wine which is prepared by white wine soakage of glossy ganoderma, ginseng, fructus schizandrae, Chinaroot greenbrier rhizome and red sage root that are taken as main medicinal raw materials thereof. The glossy ganoderma-ginseng sedative wine of the invention is prepared by scientific compatibility of medicines of the glossy ganoderma, the ginseng, the fructus schizandrae, the Chinaroot greenbrier rhizome and the red sage root, the compatibility of medicines is scientific and reasonable, the preparation process is simple and easy, and the invention is convenient for drinking and has outstanding health care effect on human body after long time drinking.

The invention discloses a soothing and antipruritic body wash. The soothing and antipruritic body wash contains 0.03-1 part of Xylostella schizophrenia extract, 0.05-1.6 parts of Ling Xiaohua extract, and 0.07-2 parts of gorgonian coral extract. It overcomes the shortcomings that most of the current shower gels are only used for cleaning and have a single effect.

The invention provides an organic compound applicable to anesthetics, which can be used as a sedative/hypnotic and for anesthetization.

The present invention relates to compounds of the general formula

wherein

• R¹ is cycloalkyl, substituted by OR or is 2-(7-oxa-bicyclo[2.2.1]hept-1-yl)-ethyl; R is hydrogen, lower alkyl or C(O)-lower alkyl; X is —CHR′—; and R′ is hydrogen or lower alkyl; and pharmaceutically acceptable acid addition salts, optically pure enantiomeres, racemates or diastereomeric mixtures thereof for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse, or for use as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for coronary artery disease and heart failure.

The invention discloses a multifunctional wet tissue for preventing mosquitoes. The preparation method of the wet tissue includes: preparation of traditional Chinese medicine components; preparation of medicament; preparation of wet tissue; radiation sterilization. The wet wipes of the present invention can effectively prevent mosquito bites through the proportioning of various traditional Chinese medicine ingredients, and irradiate and sterilize the packaged wet wipes through dose control, effectively improving the use effect and validity period of the wet wipes. In addition, the wipes also have multifunctional functions such as sterilization, food aid and tranquilization. The wet towel has been practically used and verified, and the implementation effect is remarkable.

An external defibrillator system such as a WCD is also capable of providing transthoracic pacing and drug delivery (e.g., pain-reducing drugs and/or a sedatives) to a patient. The drug(s) may be included in the therapy electrode electrolyte and dispensed for defibrillation, cardioversion and/or pacing therapy. Alternatively, the drug(s) may be stored in a separate reservoir and dispensed during pacing therapy. The drug(s) may be dispensed to a patient after a successful defibrillation therapy. The pacing therapy may be delivered a set time-period after the drug(s) were dispensed. A relatively small electric current may be delivered to the area of the patient on which the drug(s) were dispensed to facilitate drug absorption.

The invention relates to a drug combination preparation for inducing mild hypothermia and its application. The drug combination preparation for inducing mild hypothermia includes anesthetics, thermoregulators and sedatives. The dosage of the anesthetics is 10-500 mg/kg. The dosage of the thermoregulator is 5-50 mg/kg, and the dosage of the sedative is 5-50 mg/kg. The pharmaceutical combination preparation of the present invention can reduce the stress response and prevent skin frostbite when inducing regulatory mild hypothermia, quickly reach the target temperature, significantly reduce the metabolism of the drug recipient, have small fluctuations in body temperature, and control blood sugar within the normal range. First aid for chemical or drug poisoning, hypoxia, trauma, ischemia, endotoxemia, skin burns, hypoglycemia, etc.